Neogen (NEOG)
Maker of food-safety diagnostics, hygiene systems, and animal-care products.
Something off on this page? Send us feedback.
Sells food and feed testing consumables, culture media, hygiene-monitoring systems, instruments, and analytics software, alongside veterinary, diagnostic, and pest-control products. Food Safety generates most revenue, international customers contribute slightly more than half of sales, and the global genomics-services business is under agreement to be sold.
Develops and manufactures food and animal safety products through two reporting segments. Food Safety supplies mostly single-use tests, culture media, hygiene-monitoring systems, instruments, and analytics software for detecting pathogens, spoilage organisms, allergens, natural toxins, and sanitation failures. Animal Safety sells veterinary instruments and disposables, pharmaceuticals, vaccines, parasiticides, diagnostics, and rodent and insect control products, while its global genomics-services business remains under agreement to be sold to Zoetis.
Generates most revenue from Food Safety and slightly more than half of sales outside the United States. Its recurring workflow pairs proprietary assays and consumables with readers, software, training, and technical support. Operations depend on regulated product approvals and validations, third-party instrument suppliers, and completion of the Petrifilm manufacturing transfer from 3M to Lansing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 26, 2026 | Piper Sandler | Upgrade | ||
| Aug 3, 2026 | Piper Sandler | Reiterate | Rating: —Target: $10 | Target: $13 |
| Jan 12, 2026 | Piper Sandler | Reiterate | Rating: —Target: $6.50 | Target: $10 |
| Jan 9, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $12 |
| Dec 10, 2025 | CJS Securities | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, May 31, 2026Cash & short-term investments $185.5M · Total debt $793.3M · Total assets $3.35B · Shareholders' equity $2.09B
- Revenue
- $225.3M
- Operating income
- $3.1M
- Net income
- −$11.3M
No dividends on record.
| Institutions | 110.26% | 240.42M shares | |
|---|---|---|---|
| 325 holders · as of Jun 30, 2026 | |||
| Insiders | 0.59% | 1.28M shares | |
| 20 holders · as of Aug 14, 2026 | |||
| Adds to | 110.85% | ||
218.06M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 110.85%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.33% | 33.43M | as of Jun 30, 2026 |
Neuberger Berman Group LLCInstitution | 7.60% | 16.57M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.98% | 13.04M | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 4.51% | 9.83M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.43% | 9.66M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 4, 2026 | Mikheal Nassif | director, officer: CEO | +370 | $11.81 |
| Feb 17, 2026 | Mikheal Nassif | director, officer: CEO | +23 | $10.94 |
| Jan 26, 2026 | Mikheal Nassif | director, officer: CEO | +25 | $9.86 |
| Feb 2, 2026 | Mikheal Nassif | director, officer: CEO | +24 | $10.00 |
| Jan 16, 2026 | Mikheal Nassif | director, officer: CEO | +137 | $9.33 |
- Thermo Fisher Scientific
Broad food-safety workflow rival in PCR, media, and automation
- Bio-Rad Laboratories
Food pathogen PCR and chromogenic-media rival
- IDEXX Laboratories
Livestock, dairy, and poultry diagnostics peer
- Zoetis
Animal-health diagnostics and precision-livestock peer
- BD
Culture-media rival through Difco and BBL formulations
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Neogen | $14.05 | +3.20% | $2.97B | — | 47.9 | 3.4 | −0.1% |
| Thermo Fisher Scientific | $658.10 | −0.10% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Bio-Rad Laboratories | $378.00 | +0.18% | $10.16B | 45.7 | 36.7 | 3.9 | −0.1% |
| IDEXX Laboratories | $517.18 | +0.36% | $40.65B | 36.5 | 33.2 | 8.9 | +9.7% |
| Zoetis | $71.48 | +0.21% | $29.90B | 11.8 | 11.5 | 3.1 | +0.3% |
| BD | $181.25 | +0.30% | $49.79B | 54.4 | 13.7 | 2.4 | −9.6% |
| Median | 36.5 | 25.1 | 3.9 | +0.3% |